Thera-SAbDab

GALVOKIMIG1

>   Structural Summary
TherapeuticGalvokimig1
Target 1IL17A and IL17F
Heavy Chain 1EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS
Light Chain 1AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 StructureNone
Target 2ALB
Heavy Chain 2EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKCLEWIGIIWASGTTFYATWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGTLVTVSS
Light Chain 2DIQMTQSPSSVSASVGDRVTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGGGYSSISDTTFGCGTKVEIK
100% seqID Fv 2 StructureNone
99% seqID Fv 2 Structure5fuo [Fvs: HL], 5fuz [Fvs: HL]
95-98% seqID Fv 2 StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Galvokimig1.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.13%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 101 102 103 104 105 106 107 108 109 110 111 112 113
galvokimig1 Fv 2 E V Q L L E S G G G L V Q P G G S L R L S C A V S G I D L S N Y A I N W V R Q A P G K C L E W I G I I W A S G T T F Y A T W A K G R F T I S R D N S K N T V Y L Q M N S L R A E D T A V Y Y C A R T V P G Y S T A P Y F D L W G Q G T L V T V S S
5fuo E V Q L L E S G G G L V Q P G G S L R L S C A V S G I D L S N Y A I N W V R Q A P G K G L E W I G I I W A S G T T F Y A T W A K G R F T I S R D N S K N T V Y L Q M N S L R A E D T A V Y Y C A R T V P G Y S T A P Y F D L W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 96 97 98 99 100 101 102 103 104 105 106 107
galvokimig1 Fv 2 D I Q M T Q S P S S V S A S V G D R V T I T C Q S S P S V W S N F L S W Y Q Q K P G K A P K L L I Y E A S K L T S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C G G G Y S S I S D T T F G C G T K V E I K
5fuo D I Q M T Q S P S S V S A S V G D R V T I T C Q S S P S V W S N F L S W Y Q Q K P G K A P K L L I Y E A S K L T S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C G G G Y S S I S D T T F G G G T K V E I K
Sequence identity: 99.13%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 101 102 103 104 105 106 107 108 109 110 111 112 113
galvokimig1 Fv 2 E V Q L L E S G G G L V Q P G G S L R L S C A V S G I D L S N Y A I N W V R Q A P G K C L E W I G I I W A S G T T F Y A T W A K G R F T I S R D N S K N T V Y L Q M N S L R A E D T A V Y Y C A R T V P G Y S T A P Y F D L W G Q G T L V T V S S
5fuz E V Q L L E S G G G L V Q P G G S L R L S C A V S G I D L S N Y A I N W V R Q A P G K G L E W I G I I W A S G T T F Y A T W A K G R F T I S R D N S K N T V Y L Q M N S L R A E D T A V Y Y C A R T V P G Y S T A P Y F D L W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 96 97 98 99 100 101 102 103 104 105 106 107
galvokimig1 Fv 2 D I Q M T Q S P S S V S A S V G D R V T I T C Q S S P S V W S N F L S W Y Q Q K P G K A P K L L I Y E A S K L T S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C G G G Y S S I S D T T F G C G T K V E I K
5fuz D I Q M T Q S P S S V S A S V G D R V T I T C Q S S P S V W S N F L S W Y Q Q K P G K A P K L L I Y E A S K L T S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C G G G Y S S I S D T T F G G G T K V E I K
>   Metadata
FormatTrispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Bispecific entry
IsotypeG1;na
Highest Clinical Trial (Aug '24)TBC
Estimated StatusActive
Recorded Developmental Technology
INN Year Proposed2023
INN Year RecommendedNone
Companies InvolvedTBC
Conditions ApprovedTBC
Conditions ActiveTBC
Conditions DiscontinuedTBC
NotesG1(VH-CH1-h)-scFv_L-kappa segment. Fv1 identical to Bimekizumab. Fv2 identical to Donzakimig Fv2.

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy